About Arrowhead Pharmaceuticals, Inc.
https://arrowheadpharma.comArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
CEO
Christopher R. Anzalone
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2011-11-17 | Reverse | 1:10 |
| 2004-01-20 | Reverse | 1:65 |
ETFs Holding This Stock
Summary
Showing Top 3 of 185
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
B of A Securities
Buy
HC Wainwright & Co.
Buy
Chardan Capital
Buy
B. Riley Securities
Buy
RBC Capital
Outperform
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:20.22M
Value:$1.33B
VANGUARD GROUP INC
Shares:16.04M
Value:$1.06B
BLACKROCK INC.
Shares:15.68M
Value:$1.03B
Summary
Showing Top 3 of 379
About Arrowhead Pharmaceuticals, Inc.
https://arrowheadpharma.comArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $27.77M ▼ | $187.09M ▲ | $-175.24M ▼ | -631.11% ▼ | $-1.26 ▼ | $-148.48M ▼ |
| Q2-2025 | $542.71M ▲ | $161.51M ▼ | $370.44M ▲ | 68.26% ▲ | $2.78 ▲ | $397.34M ▲ |
| Q1-2025 | $2.5M ▼ | $163.91M ▲ | $-173.09M ▼ | -6.92K% ▼ | $-1.39 ▲ | $-148.23M ▲ |
| Q4-2024 | $23.59M ▲ | $162.2M ▼ | $-170.54M ▲ | -722.95% ▼ | $-1.4 ▼ | $-153.13M ▲ |
| Q3-2024 | $0 | $176.14M | $-170.79M | 0% | $-1.38 | $-164.1M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $900.37M ▼ | $1.38B ▼ | $860.81M ▼ | $522.31M ▼ |
| Q2-2025 | $1.1B ▲ | $1.57B ▲ | $889.27M ▼ | $683.32M ▲ |
| Q1-2025 | $552.93M ▼ | $1.01B ▼ | $957.62M ▲ | $52.59M ▼ |
| Q4-2024 | $680.96M ▲ | $1.14B ▲ | $948.74M ▲ | $185.44M ▼ |
| Q3-2024 | $436.67M | $883.76M | $544.78M | $330.55M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-178.65M ▼ | $-154.72M ▼ | $141.39M ▲ | $-42.68M ▼ | $-55.92M ▼ | $-157.08M ▼ |
| Q2-2025 | $367.86M ▲ | $460.05M ▲ | $-420.21M ▼ | $92.38M ▲ | $131.82M ▲ | $454.76M ▲ |
| Q1-2025 | $-175.22M ▼ | $-146.27M ▼ | $76.91M ▲ | $20.63M ▼ | $-48.8M ▼ | $-153.79M ▲ |
| Q4-2024 | $-173.34M ▲ | $-137.22M ▼ | $-222.92M ▼ | $389.09M ▲ | $33.29M ▲ | $-161.5M ▼ |
| Q3-2024 | $-173.98M | $-115.42M | $6.95M | $50.39M | $-58.3M | $-129.87M |
CEO
Christopher R. Anzalone
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2011-11-17 | Reverse | 1:10 |
| 2004-01-20 | Reverse | 1:65 |
ETFs Holding This Stock
Summary
Showing Top 3 of 185
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
B of A Securities
Buy
HC Wainwright & Co.
Buy
Chardan Capital
Buy
B. Riley Securities
Buy
RBC Capital
Outperform
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:20.22M
Value:$1.33B
VANGUARD GROUP INC
Shares:16.04M
Value:$1.06B
BLACKROCK INC.
Shares:15.68M
Value:$1.03B
Summary
Showing Top 3 of 379